Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 1 2Neurofibromatoses 2Neurofibroma, Plexiform 2Glioma 2Vascular Malformations 1Skin Diseases, Vascular 1Primary Malignant Peripheral Nerve Sheath Tumors 1Neurofibroma 1NF1 1Multiple Myeloma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioblastoma 1Central Nervous System Neoplasms 1Arteriovenous Malformations 1Advanced Solid Tumor 1

Interventions

AZD 6244 4trametinib 2mirdametinib 2dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neurofibroma, Plexiform × mirdametinib × 90 days × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡